Tejas Savant
Stock Analyst at Morgan Stanley
(2.37)
# 2,478
Out of 5,170 analysts
256
Total ratings
42.36%
Success rate
-1.33%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Underweight | $48 → $37 | $32.78 | +12.87% | 16 | Mar 6, 2026 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $24 → $19 | $15.17 | +25.25% | 4 | Mar 6, 2026 | |
| PSNL Personalis | Maintains: Equal-Weight | $11 → $10 | $7.19 | +39.08% | 15 | Mar 5, 2026 | |
| TEM Tempus AI | Maintains: Overweight | $85 → $70 | $48.74 | +43.62% | 7 | Mar 3, 2026 | |
| NTRA Natera | Maintains: Overweight | $265 → $250 | $202.73 | +23.32% | 16 | Mar 3, 2026 | |
| GRAL GRAIL | Maintains: Equal-Weight | $110 → $60 | $48.47 | +23.79% | 4 | Feb 24, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $470.21 | +42.49% | 16 | Dec 2, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $250 → $265 | $166.47 | +59.19% | 12 | Dec 2, 2025 | |
| TXG 10x Genomics | Downgrades: Equal-Weight | $17 → $20 | $18.38 | +8.81% | 16 | Dec 2, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $69 → $76 | $75.33 | +0.89% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $16 | $13.50 | +18.52% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $126.59 | -17.06% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $7.61 | +57.69% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $8.18 | -2.20% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $7 | $4.51 | +55.21% | 9 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $8.29 | -15.56% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.03 | +65.02% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $4.75 | +342.11% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.40 | +42.86% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $6.91 | +478.87% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.75 | +118.18% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.86 | +105.76% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $2.50 | +10.00% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.73 | +479.71% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $89.08 | -18.05% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $153.05 | +63.35% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $16.30 | +513.50% | 5 | May 12, 2022 |
Veracyte
Mar 6, 2026
Maintains: Underweight
Price Target: $48 → $37
Current: $32.78
Upside: +12.87%
Stevanato Group
Mar 6, 2026
Maintains: Equal-Weight
Price Target: $24 → $19
Current: $15.17
Upside: +25.25%
Personalis
Mar 5, 2026
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $7.19
Upside: +39.08%
Tempus AI
Mar 3, 2026
Maintains: Overweight
Price Target: $85 → $70
Current: $48.74
Upside: +43.62%
Natera
Mar 3, 2026
Maintains: Overweight
Price Target: $265 → $250
Current: $202.73
Upside: +23.32%
GRAIL
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $110 → $60
Current: $48.47
Upside: +23.79%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $470.21
Upside: +42.49%
IQVIA Holdings
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $166.47
Upside: +59.19%
10x Genomics
Dec 2, 2025
Downgrades: Equal-Weight
Price Target: $17 → $20
Current: $18.38
Upside: +8.81%
Hologic
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $69 → $76
Current: $75.33
Upside: +0.89%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $13.50
Upside: +18.52%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $126.59
Upside: -17.06%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $7.61
Upside: +57.69%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $8.18
Upside: -2.20%
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $4.51
Upside: +55.21%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $8.29
Upside: -15.56%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.03
Upside: +65.02%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $4.75
Upside: +342.11%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.40
Upside: +42.86%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $6.91
Upside: +478.87%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.75
Upside: +118.18%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.86
Upside: +105.76%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $2.50
Upside: +10.00%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.73
Upside: +479.71%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $89.08
Upside: -18.05%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $153.05
Upside: +63.35%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $16.30
Upside: +513.50%